Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-23-126947
Filing Date
2023-04-28
Accepted
2023-04-28 16:12:09
Documents
16
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A d483659d10ka.htm   iXBRL 10-K/A 351987
2 EX-31.1 d483659dex311.htm EX-31.1 3950
3 EX-31.2 d483659dex312.htm EX-31.2 3947
  Complete submission text file 0001193125-23-126947.txt   620771

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA aldx-20221231.xsd EX-101.SCH 5015
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE aldx-20221231_cal.xml EX-101.CAL 701
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE aldx-20221231_def.xml EX-101.DEF 18446
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE aldx-20221231_lab.xml EX-101.LAB 23572
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aldx-20221231_pre.xml EX-101.PRE 19635
10 EXTRACTED XBRL INSTANCE DOCUMENT d483659d10ka_htm.xml XML 8234
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-36332 | Film No.: 23866236
SIC: 2834 Pharmaceutical Preparations